An Overview of Current Phage Therapy: Challenges for Implementation
Naomi Hoyle, Randolph Fish, Nata Nakaidze, Satya Ambrose and Elizabeth Martin Kutter
from: Bacterial Viruses: Exploitation for Biocontrol and Therapeutics (Edited by: Aidan Coffey and Colin Buttimer). Caister Academic Press, U.K. (2020) Pages: 1-48.
Bacteriophages (phages) provide an increasingly recognised important option for the treatment of antibiotic resistant infections. This chapter will discuss key points in the history of phage therapy but will primarily focus on current advancements in phage therapeutics. We discuss compassionate use of phage therapy in the United States, Europe and Australia for severe infections caused by antibiotic resistant Acinetobacter baumannii, Carbapenemase-producing Klebsiella pneumoniae and multidrug resistant (MDR) Pseudomonas aeruginosa, among others. Challenges for implementation of phage therapy include the need for further development of therapeutic phage products in an appropriate manner for the current technology as well as clinical studies addressing gaps in the knowledge, especially in terms of dose, distribution, immune response, and legal framework, while drawing on the extensive history of phage used in other countries. Phage therapy has the potential to address a serious unmet need which has a significant economic impact, particularly the significant morbidity and mortality associated with antibiotic resistant infections read more ...